{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:02:45Z","timestamp":1791576165146,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Project of Science and Technology Bureau of Xiamen","award":["3502Z202373098"],"award-info":[{"award-number":["3502Z202373098"]}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"crossref","award":["2023J01121380"],"award-info":[{"award-number":["2023J01121380"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Young\/Middle-aged Talent Cultivation Project funded by Fujian Provincial Health and Family Planning Commission and Xiamen Health and Family planning Commission","award":["2021GGB028"],"award-info":[{"award-number":["2021GGB028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-024-01685-4","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T22:49:25Z","timestamp":1737931765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neutrophil-to-lymphocyte ratio as a prognostic factor in patients with castration-resistant prostate cancer treated with docetaxel-based chemotherapy: a meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2334-3885","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"3","key":"1685_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1685_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"1685_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ucl.2012.07.003","volume":"39","author":"TW Friedlander","year":"2012","unstructured":"Friedlander TW, Ryan CJ. Targeting the androgen receptor. Urol Clin North Am. 2012;39(4):453\u201364.","journal-title":"Urol Clin North Am"},{"issue":"10","key":"1685_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","volume":"8","author":"TA Yap","year":"2011","unstructured":"Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(10):597\u2013610.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1685_CR5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242\u20135.","journal-title":"J Clin Oncol"},{"issue":"15","key":"1685_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.","journal-title":"N Engl J Med"},{"issue":"15","key":"1685_CR7","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"1685_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341.","journal-title":"Immunity"},{"issue":"10","key":"1685_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.acuro.2020.08.001","volume":"44","author":"MJ Donate-Moreno","year":"2020","unstructured":"Donate-Moreno MJ, Lorenzo-S\u00e1nchez MV, D\u00edaz de Mera-S\u00e1nchez Migall\u00f3n I, Herraiz-Raya L, Esper-Rueda JA, Legido-G\u00f3mez O, et al. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer. Actas Urol Esp (Engl Ed). 2020;44(10):692\u2013700.","journal-title":"Actas Urol Esp (Engl Ed)"},{"issue":"6","key":"1685_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.urolonc.2019.11.005","volume":"38","author":"J Stangl-Kremser","year":"2020","unstructured":"Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D\u2019Andrea D, Korn SM, Pones M, et al. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. Urol Oncol. 2020;38(6):600.e9-.e15","journal-title":"Urol Oncol"},{"issue":"7","key":"1685_CR11","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/pros.23969","volume":"80","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Sakamoto S, Rii J, Yamamoto S, Kamada S, Imamura Y, et al. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80(7):559\u201369.","journal-title":"Prostate"},{"issue":"1","key":"1685_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12943-017-0707-7","volume":"16","author":"A Ocana","year":"2017","unstructured":"Ocana A, Nieto-Jim\u00e9nez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16(1):137.","journal-title":"Mol Cancer"},{"issue":"8","key":"1685_CR13","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1007\/s11255-014-0664-7","volume":"46","author":"AT S\u00fcmb\u00fcl","year":"2014","unstructured":"S\u00fcmb\u00fcl AT, Sezer A, Abal\u0131 H, K\u00f6se F, G\u00fcltepe I, Mertsoylu H, et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 2014;46(8):1531\u20135.","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"1685_CR14","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00345-019-02658-1","volume":"37","author":"KC Koo","year":"2019","unstructured":"Koo KC, Lee JS, Ha JS, Han KS, Lee KS, Hah YS, et al. Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. World J Urol. 2019;37(11):2375\u201384.","journal-title":"World J Urol"},{"key":"1685_CR15","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.","journal-title":"BMJ"},{"issue":"4","key":"1685_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.clgc.2013.04.020","volume":"11","author":"A Linton","year":"2013","unstructured":"Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 2013;11(4):423\u201330.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"1685_CR17","first-page":"E11","volume":"114","author":"P Nuhn","year":"2014","unstructured":"Nuhn P, Vaghasia AM, Goyal J, Zhou XC, Carducci MA, Eisenberger MA, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2014;114(6):E11\u20137.","journal-title":"BJU Int"},{"issue":"21","key":"1685_CR18","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/cncr.28890","volume":"120","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120(21):3346\u201352.","journal-title":"Cancer"},{"issue":"9","key":"1685_CR19","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/iju.12839","volume":"22","author":"A Yao","year":"2015","unstructured":"Yao A, Sejima T, Iwamoto H, Masago T, Morizane S, Honda M, et al. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015;22(9):827\u201333.","journal-title":"Int J Urol"},{"issue":"4","key":"1685_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/0284186X.2016.1260772","volume":"56","author":"C Buttigliero","year":"2017","unstructured":"Buttigliero C, Pisano C, Tucci M, Vignani F, Bertaglia V, Iaconis D, et al. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Acta Oncol. 2017;56(4):555\u201362.","journal-title":"Acta Oncol"},{"issue":"4","key":"1685_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s11255-017-1524-z","volume":"49","author":"XQ Pei","year":"2017","unstructured":"Pei XQ, He DL, Tian G, Lv W, Jiang YM, Wu DP, et al. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol. 2017;49(4):629\u201335.","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"1685_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4103\/aja.aja_34_17","volume":"20","author":"KJ Wu","year":"2018","unstructured":"Wu KJ, Pei XQ, Tian G, Wu DP, Fan JH, Jiang YM, et al. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Asian J Androl. 2018;20(2):173\u20137.","journal-title":"Asian J Androl"},{"issue":"4","key":"1685_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.4103\/njcp.njcp_382_18","volume":"22","author":"JO Bello","year":"2019","unstructured":"Bello JO, Olanipekun OO, Babata AL. Prognostic value of neutrophil-to-lymphocyte ratio in castration resistant prostate cancer: single-centre study of Nigerian men. Niger J Clin Pract. 2019;22(4):511\u20135.","journal-title":"Niger J Clin Pract"},{"issue":"12","key":"1685_CR24","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1007\/s11255-019-02265-4","volume":"51","author":"YN Man","year":"2019","unstructured":"Man YN, Chen YF. Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel. Int Urol Nephrol. 2019;51(12):2189\u201399.","journal-title":"Int Urol Nephrol"},{"key":"1685_CR25","doi-asserted-by":"crossref","unstructured":"Tatenuma T, Kawahara T, Hayashi N, Hasumi H, Makiyama K, Nakaigawa N et al. The Pretherapeutic Neutrophil-to-Lymphocyte Ratio for Docetaxel-Based Chemotherapy Is Useful for Predicting the Prognosis of Japanese Patients with Castration-Resistant Prostate Cancer. BioMed Research International. 2019;2019.","DOI":"10.1155\/2019\/2535270"},{"key":"1685_CR26","doi-asserted-by":"crossref","unstructured":"Jiang ZG, Liao SG. Baseline neutrophil-lymphocyte ratio is associated with outcomes in patients with castration-resistant prostate cancer treated with Docetaxel in South China. Med (United States). 2021;100(39).","DOI":"10.1097\/MD.0000000000027361"},{"issue":"1","key":"1685_CR27","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1097\/CAD.0000000000001170","volume":"33","author":"H Kobayashi","year":"2022","unstructured":"Kobayashi H, Shiota M, Sato N, Kobayashi S, Matsumoto T, Monji K, et al. Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. Anti-cancer Drugsp. 2022;33(1):e541\u20137.","journal-title":"Anti-cancer Drugsp"},{"key":"1685_CR28","doi-asserted-by":"crossref","unstructured":"Neuberger M, Goly N, Skladny J, Milczynski V, Wei\u00df C, Wessels F et al. Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort. J Cancer Res Clin Oncol. 2022.","DOI":"10.1007\/s00432-022-04220-w"},{"issue":"4","key":"1685_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"2","key":"1685_CR30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41391-020-0209-3","volume":"23","author":"Y Guan","year":"2020","unstructured":"Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020;23(2):220\u201331.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1685_CR31","doi-asserted-by":"crossref","unstructured":"Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol. 2014;6(1).","DOI":"10.1177\/1756287213509677"},{"issue":"7","key":"1685_CR32","first-page":"474","volume":"122","author":"R Zahorec","year":"2021","unstructured":"Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122(7):474\u201388.","journal-title":"Bratisl Lek Listy"},{"key":"1685_CR33","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ijsu.2019.10.043","volume":"72","author":"S Su","year":"2019","unstructured":"Su S, Liu L, Li C, Zhang J, Li S. Prognostic role of pretreatment derived neutrophil to lymphocyte ratio in urological cancers: a systematic review and meta-analysis. Int J Surg. 2019;72:146\u201353.","journal-title":"Int J Surg"},{"issue":"3","key":"1685_CR34","doi-asserted-by":"publisher","first-page":"e2544","DOI":"10.1097\/MD.0000000000002544","volume":"95","author":"X Yin","year":"2016","unstructured":"Yin X, Xiao Y, Li F, Qi S, Yin Z, Gao J. Prognostic role of Neutrophil-to-lymphocyte ratio in prostate Cancer: a systematic review and Meta-analysis. Med (Baltim). 2016;95(3):e2544.","journal-title":"Med (Baltim)"},{"issue":"4","key":"1685_CR35","doi-asserted-by":"publisher","first-page":"e0153981","DOI":"10.1371\/journal.pone.0153981","volume":"11","author":"L Tang","year":"2016","unstructured":"Tang L, Li X, Wang B, Luo G, Gu L, Chen L, et al. Prognostic Value of Neutrophil-to-lymphocyte ratio in localized and advanced prostate Cancer: a systematic review and Meta-analysis. PLoS ONE. 2016;11(4):e0153981.","journal-title":"PLoS ONE"},{"key":"1685_CR36","doi-asserted-by":"publisher","first-page":"22089","DOI":"10.1038\/srep22089","volume":"6","author":"X Gu","year":"2016","unstructured":"Gu X, Gao X, Li X, Qi X, Ma M, Qin S, et al. Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients. Sci Rep. 2016;6:22089.","journal-title":"Sci Rep"},{"issue":"3","key":"1685_CR37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","volume":"11","author":"M Markman","year":"2003","unstructured":"Markman M. Managing taxane toxicities. Support Care Cancer. 2003;11(3):144\u20137.","journal-title":"Support Care Cancer"},{"key":"1685_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.breast.2018.12.014","volume":"44","author":"V Graziano","year":"2019","unstructured":"Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33\u20138.","journal-title":"Breast"},{"issue":"1","key":"1685_CR39","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1186\/s12885-019-5903-y","volume":"19","author":"T Hirahara","year":"2019","unstructured":"Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, et al. Combined neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19(1):672.","journal-title":"BMC Cancer"},{"issue":"7","key":"1685_CR40","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1007\/s00405-021-07233-2","volume":"279","author":"N Woodley","year":"2022","unstructured":"Woodley N, Rogers ADG, Turnbull K, Slim MAM, Ton T, Montgomery J, et al. Prognostic scores in laryngeal cancer. Eur Arch Otorhinolaryngol. 2022;279(7):3705\u201315.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"1685_CR41","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1053\/j.seminoncol.2023.01.006","volume":"49","author":"D Smith","year":"2022","unstructured":"Smith D, Raices M, Cayol F, Corvatta F, Caram L, Dietrich A. Is the neutrophil-to-lymphocyte ratio a prognostic factor in non-small cell lung cancer patients who receive adjuvant chemotherapy? Semin Oncol. 2022;49(6):482\u20139.","journal-title":"Semin Oncol"},{"issue":"6","key":"1685_CR42","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/jso.24549","volume":"115","author":"T Yang","year":"2017","unstructured":"Yang T, Zhu J, Zhao L, Mai K, Ye J, Huang S, et al. Lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio are superior inflammation-based predictors of recurrence in patients with hepatocellular carcinoma after hepatic resection. J Surg Oncol. 2017;115(6):718\u201328.","journal-title":"J Surg Oncol"},{"issue":"4","key":"1685_CR43","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1172\/JCI108159","volume":"56","author":"DC Dale","year":"1975","unstructured":"Dale DC, Fauci AS, Guerry DI, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975;56(4):808\u201313.","journal-title":"J Clin Invest"},{"issue":"3","key":"1685_CR44","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/JLB.3MR0717-292R","volume":"103","author":"MR Galdiero","year":"2018","unstructured":"Galdiero MR, Varricchi G, Loffredo S, Mantovani A, Marone G. Roles of neutrophils in cancer growth and progression. J Leukoc Biol. 2018;103(3):457\u201364.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"1685_CR45","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","volume":"26","author":"RJ Kishton","year":"2017","unstructured":"Kishton RJ, Sukumar M, Restifo NP. Metabolic regulation of T cell longevity and function in Tumor Immunotherapy. Cell Metab. 2017;26(1):94\u2013109.","journal-title":"Cell Metab"},{"key":"1685_CR46","doi-asserted-by":"crossref","unstructured":"Zaffaroni M, Vincini MG, Corrao G, Lorubbio C, Repetti I, Mastroleo F et al. Investigating Nutritional and Inflammatory Status as predictive biomarkers in oligoreccurent prostate Cancer-A RADIOSA Trial Preliminary Analysis. Nutrients. 2023;15(21).","DOI":"10.3390\/nu15214583"},{"issue":"3","key":"1685_CR47","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/annonc\/mdt581","volume":"25","author":"R Leibowitz-Amit","year":"2014","unstructured":"Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25(3):657\u201362.","journal-title":"Ann Oncol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01685-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-024-01685-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-024-01685-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T10:35:10Z","timestamp":1737974110000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-024-01685-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/s12894-024-01685-4","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}